Briacell Therapeutics Corp

NASDAQ BCTX

Data sourced from iex and EODHD
Download Data

Briacell Therapeutics Corp Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Briacell Therapeutics Corp Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Briacell Therapeutics Corp 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Briacell Therapeutics Corp 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Briacell Therapeutics Corp average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.
NASDAQ: BCTX

Briacell Therapeutics Corp

CEO Dr. William V. Williams M.D.
IPO Date Feb. 24, 2021
Location Canada
Headquarters Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Employees 16
Sector Healthcare
Industry Biotechnology
Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email